TransEnterix, Inc. (NYSEAMERICAN:TRXC) Director William N. Starling, Jr. sold 1,700,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $6.40, for a total transaction of $10,880,000.00. Following the completion of the sale, the director now directly owns 66,987 shares in the company, valued at $428,716.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
TRXC traded down $0.20 during trading hours on Thursday, hitting $6.04. 6,692,400 shares of the company’s stock were exchanged, compared to its average volume of 4,840,811. TransEnterix, Inc. has a 12-month low of $1.27 and a 12-month high of $6.98.
TransEnterix (NYSEAMERICAN:TRXC) last announced its earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). TransEnterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%. The firm had revenue of $6.39 million for the quarter, compared to the consensus estimate of $6.20 million.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new stake in TransEnterix during the 2nd quarter worth approximately $101,000. Amalgamated Bank purchased a new stake in TransEnterix during the 2nd quarter worth approximately $104,000. Ardsley Advisory Partners purchased a new stake in TransEnterix during the 2nd quarter worth approximately $109,000. State Board of Administration of Florida Retirement System purchased a new stake in TransEnterix during the 2nd quarter worth approximately $138,000. Finally, Cozad Asset Management Inc. purchased a new stake in TransEnterix during the 2nd quarter worth approximately $228,000.
Several equities research analysts recently weighed in on the stock. BTIG Research reaffirmed a “hold” rating on shares of TransEnterix in a research note on Tuesday. Zacks Investment Research raised shares of TransEnterix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $5.50 target price on shares of TransEnterix in a research note on Thursday, July 5th.
TransEnterix Company Profile
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Recommended Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.